MDMA Assisted Therapy Shows Promising Results For Veterans With PTSD And Alcohol Use Disorder
A pilot study reveals that MDMA-assisted therapy shows promising results in treating military veterans struggling with both PTSD and alcohol use disorder.
A pioneering clinical trial involving military veterans has yielded encouraging results for a novel treatment approach targeting the dual burden of post-traumatic stress disorder (PTSD) and alcohol use disorder. Researchers from Brown University found that MDMA-assisted therapy is not only feasible and safe but also shows significant promise in alleviating the psychological symptoms that often drive veterans toward substance misuse.
Addressing a Persistent Clinical Challenge
For many military veterans, the intersection of PTSD and alcohol dependency creates a cycle of severe impairment that remains notoriously difficult to treat. Standard protocols, such as cognitive processing therapy, often struggle with high dropout rates and limited long-term success. Given the high stakes, including an elevated risk of suicide, the clinical community has been searching for more effective, durable interventions.
“As a psychologist who works with military veterans, I have personally witnessed the shortcomings of the standard treatment models,” said Christy Capone, a study coauthor and assistant professor of psychiatry and human behavior at Brown University’s Warren Alpert Medical School. “This is an urgent matter: I am not alone among people who treat this population in losing patients to suicide because of PTSD and alcohol use disorder.”
The Therapeutic Protocol
The study, published in the journal Alcohol, followed a structured therapeutic arc. Participants underwent 11 sessions spanning five months. This included three preparatory meetings, two sessions where MDMA was administered alongside psychotherapy, and six integration sessions. During the integration phase, clinicians helped veterans process the emotional insights gained during the dosing sessions and apply them to their daily lives.
The retention rate was notably high, with nine out of ten enrolled participants completing the full course of treatment. For a population often prone to attrition in clinical settings, this level of engagement suggests that the intensive, two-part therapy model is highly tolerable for veterans.
Clinical Outcomes and Future Directions
The primary measure of success was the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). Results were striking: participants saw an average reduction of over 22 points on the scale, representing a transition from severe to mild PTSD symptoms. According to researchers, a reduction of 10 to 15 points is typically considered clinically meaningful, making the observed outcome particularly significant.
While the study also tracked alcohol consumption—recording a 31% reduction in drinks per drinking day and a 54% decrease in heavy drinking days—researchers noted that these findings were not strictly categorized as clinically significant due to the lack of a control group and pre-trial behavioral changes among some participants. However, importantly, none of the participants experienced an escalation in substance use, and no serious adverse events were documented.
This study arrives at a critical juncture for MDMA-based research. While the FDA designated MDMA as a breakthrough therapy for PTSD in 2017, the agency declined formal approval in 2024, citing concerns regarding methodology and efficacy. The Brown University team emphasizes that their current findings provide necessary, rigorous data that could help satisfy regulatory requirements for future approval.
Looking ahead, the research group is shifting its focus to even more robust testing. They are currently collaborating with the Providence VA Medical Center on a randomized clinical trial that pits therapeutic doses of MDMA against an active control (a low dose of the drug). Additionally, the team plans to analyze brain imaging data collected during the study to identify potential biomarkers associated with the treatment’s success.
This article has been fact checked for accuracy, with information verified against reputable sources. Learn more about us and our editorial process.
Last reviewed on .
Article history
- Latest version
Reference(s)
- Eaton, Erica., et al. “MDMA-assisted therapy for veterans with comorbid posttraumatic stress disorder and alcohol use disorder: Clinical outcomes from the first open-label pilot trial.” Alcohol, vol. 137, December 1, 2026, pp. 107464 Elsevier BV, doi: 10.1016/j.alcohol.2026.107464. <https://doi.org/10.1016/j.alcohol.2026.107464>.
Cite this page:
- Posted by Sana Malik